M
Michael H. Nantz
Researcher at University of Louisville
Publications - 118
Citations - 4177
Michael H. Nantz is an academic researcher from University of Louisville. The author has contributed to research in topics: Gene delivery & Transfection. The author has an hindex of 31, co-authored 117 publications receiving 3967 citations. Previous affiliations of Michael H. Nantz include University of California, Davis.
Papers
More filters
Journal ArticleDOI
Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium*
Carlo Selmi,Carlo Selmi,David L. Balkwill,Pietro Invernizzi,Aftab A. Ansari,Ross L. Coppel,Mauro Podda,Patrick S.C. Leung,Thomas P. Kenny,Judy Van de Water,Michael H. Nantz,Mark J. Kurth,M. Eric Gershwin +12 more
TL;DR: It is proposed that N. aromaticivorans is a candidate for the induction of PBC, based on protein homology, capacity to metabolize xenobiotics as well as modulate estrogens, its presence in feces, and specific immunologic response.
Journal ArticleDOI
Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds
Luis J. V. Galietta,Mark F. Springsteel,Masahiro Eda,Edmund J. Niedzinski,Kolbot By,Makhluf J. Haddadin,Mark J. Kurth,Michael H. Nantz,Alan S. Verkman +8 more
TL;DR: The results establish an efficient screening procedure to identify CFTR activators and inhibitors and have identified 7,8-benzoflavones and pyrazolo derivatives as novel classes of CFTR Activators.
Journal ArticleDOI
Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications.
TL;DR: The asialoglycoprotein receptor (ASGP-R) on mammalian hepatocytes provides a unique means for the development of liver-specific carriers, such as liposomes, recombinant lipoproteins, and polymers for drug or gene delivery to the liver, especially to hepatocytes as mentioned in this paper.
Journal ArticleDOI
Chemical Xenobiotics and Mitochondrial Autoantigens in Primary Biliary Cirrhosis: Identification of Antibodies against a Common Environmental, Cosmetic, and Food Additive, 2-Octynoic Acid
Katsushi Amano,Patrick S.C. Leung,Roman Rieger,Chao Quan,Xiaobing Wang,Jan Marik,Yat Fan Suen,Mark J. Kurth,Michael H. Nantz,Aftab A. Ansari,Kit S. Lam,Mikio Zeniya,Eiji Matsuura,Ross L. Coppel,M. Eric Gershwin +14 more
TL;DR: It is hypothesized that in PBC the lipoyl domain of the immunodominant E2 component of pyruvate dehydrogenase (PDC-E2) is replaced by a chemical xenobiotic mimic, which is sufficient to break self-tolerance.
Journal ArticleDOI
Phenylglycine and Sulfonamide Correctors of Defective ΔF508 and G551D Cystic Fibrosis Transmembrane Conductance Regulator Chloride-Channel Gating
Nicoletta Pedemonte,N.D. Sonawane,Alessandro Taddei,Jie Hu,Olga Zegarra-Moran,Yat Fan Suen,Lori I. Robins,Christopher W. Dicus,Dan Willenbring,Michael H. Nantz,Mark J. Kurth,Luis J. V. Galietta,Alan S. Verkman +12 more
TL;DR: Phenylglycine and sulfonamide compounds may be useful for monotherapy of cystic fibrosis caused by gating mutants and possibly for a subset of ΔF508 subjects with significant ΔF504-CFTR plasma-membrane expression.